{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:34:50Z","timestamp":1789601690399,"version":"build-2803163510"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advances in experimental and computational technologies continue to grow rapidly to provide novel avenues for the treatment of neurodegenerative disorders. Despite this, there remain only a handful of drugs that have shown success in late-stage clinical trials for Tau-associated neurodegenerative disorders. The most commonly prescribed treatments are symptomatic treatments such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers that were approved for use in Alzheimer\u2019s disease. As diagnostic screening can detect disorders at earlier time points, the field needs pre-symptomatic treatments that can prevent, or significantly delay the progression of these disorders (Koychev et al., 2019). These approaches may be different from late-stage treatments that may help to ameliorate symptoms and slow progression once symptoms have become more advanced should early diagnostic screening fail. This mini-review will highlight five key avenues of academic and industrial research for identifying therapeutic strategies to treat Tau-associated neurodegenerative disorders. These avenues include investigating (1) the broad class of chemicals termed \u201csmall molecules\u201d; (2) adaptive immunity through both passive and active antibody treatments; (3) innate immunity with an emphasis on microglial modulation; (4) synaptic compartments with the view that Tau-associated neurodegenerative disorders are synaptopathies. Although this mini-review will focus on Alzheimer\u2019s disease due to its prevalence, it will also argue the need to target other tauopathies, as through understanding Alzheimer\u2019s disease as a Tau-associated neurodegenerative disorder, we may be able to generalize treatment options. For this reason, added detail linking back specifically to Tau protein as a direct therapeutic target will be added to each topic.<\/jats:p>","DOI":"10.4103\/1673-5374.373670","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T05:20:42Z","timestamp":1681363242000},"page":"2633-2637","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells"],"prefix":"10.4103","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-5763","authenticated-orcid":false,"given":"Miranda","family":"Robbins","sequence":"first","affiliation":[{"name":"MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Ave, Trumpington, Cambridge, UK; University of Cambridge, Department of Zoology, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"R1-20260525","doi-asserted-by":"crossref","first-page":"eabp9540","DOI":"10.1126\/sciadv.abp9540","article-title":"Fragment-based computational design of antibodies targeting structured epitopes","volume":"8","author":"Aguilar","year":"2022","journal-title":"Sci Adv"},{"key":"R2-20260525","doi-asserted-by":"crossref","first-page":"107327","DOI":"10.1016\/j.nlm.2020.107327","article-title":"Guanfacine's mechanism of action in treating prefrontal cortical disorders:Successful translation across species","volume":"176","author":"Arnsten","year":"2020","journal-title":"Neurobiol Learn Mem"},{"key":"R3-20260525","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2and tau:the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"},{"key":"R4-20260525","doi-asserted-by":"crossref","first-page":"eaaz7825","DOI":"10.1126\/sciadv.aaz7825","article-title":"Epitope-directed antibody selection by site-specific photocrosslinking","volume":"6","author":"Chen","year":"2020","journal-title":"Sci Adv"},{"key":"R5-20260525","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.cmet.2019.01.001","article-title":"RNA-targeted therapeutics","volume":"29","author":"Crooke","year":"2019","journal-title":"Cell Metab"},{"key":"R6-20260525","first-page":"e12295","article-title":"Alzheimer's disease drug development pipeline:2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement"},{"key":"R7-20260525","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"R8-20260525","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1471-4914(01)02266-3","article-title":"Glycogen synthase kinase 3:an emerging therapeutic target","volume":"8","author":"Eldar-Finkelman","year":"2002","journal-title":"Trends Mol Med"},{"key":"R9-20260525","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12896","article-title":"The role of innate immunity in Alzheimer's disease","volume":"297","author":"Ennerfelt","year":"2020","journal-title":"Immunol Rev"},{"key":"R10-20260525","first-page":"e12126","article-title":"A vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons","volume":"7","author":"Fessel","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R11-20260525","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer's disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"R12-20260525","first-page":"80","article-title":"Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules","volume":"1","author":"Galloway","year":"2010","journal-title":"Nat Commun 2010"},{"key":"R13-20260525","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.brainres.2012.01.047","article-title":"Progranulin:an emerging target for FTLD therapies","volume":"1462","author":"Gass","year":"2012","journal-title":"Brain Res"},{"key":"R14-20260525","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol Aging"},{"key":"R15-20260525","first-page":"1645","article-title":"Mesenchymal stem cell- and extracellular vesicle-based therapies for Alzheimer\u2019s disease:progress, advantages, and challenges","volume":"18","author":"Gon\u00e7alves","year":"2023","journal-title":"Neural Regen Res"},{"key":"R16-20260525","doi-asserted-by":"crossref","first-page":"e9711","DOI":"10.15252\/emmm.201809711","article-title":"Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism","volume":"11","author":"G\u00f6tzl","year":"2019","journal-title":"EMBO Mol Med"},{"key":"R17-20260525","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcdb.2022.05.028","article-title":"Synapse pathology in Alzheimer's disease","volume":"139","author":"Griffiths","year":"2023","journal-title":"Semin Cell Dev Biol"},{"key":"R18-20260525","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cell.2010.07.032","article-title":"Fyn-Tau-amyloid:a toxic triad","volume":"142","author":"Haass","year":"2010","journal-title":"Cell"},{"key":"R19-20260525","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nat Neurosci"},{"key":"R20-20260525","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41541-022-00544-3","article-title":"Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates","volume":"7","author":"Hovakimyan","year":"2022","journal-title":"NPJ Vaccines"},{"key":"R21-20260525","first-page":"7406810","article-title":"Tau-reactive endogenous antibodies:origin, functionality, and implications for the pathophysiology of Alzheimer's disease","author":"Hromadkova","year":"2019","journal-title":"J Immunol Res"},{"key":"R22-20260525","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fnagi.2017.00311","article-title":"Expression of tau pathology-related proteins in different brain regions:a molecular basis of tau pathogenesis","volume":"9","author":"Hu","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"R23-20260525","doi-asserted-by":"crossref","first-page":"16502","DOI":"10.1074\/jbc.M611336200","article-title":"GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2","volume":"282","author":"Jain","year":"2007","journal-title":"J Biol Chem"},{"key":"R24-20260525","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","article-title":"Glycogen synthase kinase-3 (GSK3):inflammation, diseases, and therapeutics","volume":"32","author":"Jope","year":"2007","journal-title":"Neurochem Res"},{"key":"R25-20260525","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/bcj.2011.32","article-title":"Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib","volume":"1","author":"Kim","year":"2011","journal-title":"Blood Cancer J"},{"key":"R26-20260525","doi-asserted-by":"crossref","first-page":"20130144","DOI":"10.1098\/rstb.2013.0144","article-title":"Microtubule-associated protein tau is essential for long-term depression in the hippocampus","volume":"369","author":"Kimura","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R27-20260525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"R28-20260525","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cns.12684","article-title":"The neuroprotective effects of caffeine in neurodegenerative diseases","volume":"23","author":"Kolahdouzan","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"R29-20260525","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3389\/fcell.2021.609908","article-title":"The synaptic vesicle protein 2A interacts with key pathogenic factors in Alzheimer's disease:implications for treatment","volume":"9","author":"Kong","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R30-20260525","doi-asserted-by":"crossref","first-page":"e024498","DOI":"10.1136\/bmjopen-2018-024498","article-title":"Deep and frequent phenotyping study protocol:an observational study in prodromal Alzheimer's disease","volume":"9","author":"Koychev","year":"2019","journal-title":"BMJ Open"},{"key":"R31-20260525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-021-04398-9","article-title":"On the robustness of generalization of drug\u2013drug interaction models","volume":"22","author":"Kpanou","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"R32-20260525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders:the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener 2020"},{"key":"R33-20260525","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of Tau hyperphosphorylation and A\u03b21-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and \u03c31receptor agonist, in a nontransgenic mouse model of Alzheimer's disease","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"R34-20260525","doi-asserted-by":"crossref","first-page":"e054187","DOI":"10.1002\/alz.054187","article-title":"Synaptic tau and synaptogyrin-3 are promising targets to tackle tauopathies","volume":"17","author":"Largo-Barrientos","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R35-20260525","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuron.2020.12.016","article-title":"Lowering Synaptogyrin-3 expression rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation","volume":"109","author":"Largo-Barrientos","year":"2021","journal-title":"Neuron"},{"key":"R37-20260525","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep"},{"key":"R38-20260525","doi-asserted-by":"crossref","first-page":"100513","DOI":"10.1016\/j.patter.2022.100513","article-title":"Deciphering the language of antibodies using self-supervised learning","volume":"3","author":"Leem","year":"2022","journal-title":"Patterns"},{"key":"R39-20260525","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","article-title":"Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease","volume":"108","author":"Lewcock","year":"2020","journal-title":"Neuron"},{"key":"R40-20260525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.febslet.2004.04.047","article-title":"Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration","volume":"566","author":"Li","year":"2004","journal-title":"FEBS Lett"},{"key":"R41-20260525","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","article-title":"Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid","volume":"18","author":"Lle\u00f3","year":"2019","journal-title":"Mol Cell Proteomics"},{"key":"R42-20260525","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1084\/jem.20161731","article-title":"Tau deletion promotes brain insulin resistance","volume":"214","author":"Marciniak","year":"2017","journal-title":"J Exp Med"},{"key":"R43-20260525","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.15252\/embr.201743922","article-title":"TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury","volume":"18","author":"Mazaheri","year":"2017","journal-title":"EMBO Rep"},{"key":"R44-20260525","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.neuron.2018.01.022","article-title":"Synaptogyrin-3 mediates presynaptic dysfunction induced by tau","volume":"97","author":"McInnes","year":"2018","journal-title":"Neuron"},{"key":"R45-20260525","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1567205013666160819131336","article-title":"Tau, amyloid beta and deep brain stimulation:aiming to restore cognitive deficit in Alzheimer's disease","volume":"14","author":"Mondrag\u00f3n-Rodr\u00edguez","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"R46-20260525","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3233\/JAD-150746","article-title":"Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias","volume":"50","author":"Morenas-Rodr\u00edguez","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"R47-20260525","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.nbd.2006.10.018","article-title":"The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts","volume":"25","author":"Myers","year":"2006","journal-title":"Neurobiol Dis"},{"key":"R51-20260525","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881116680924","article-title":"Clinical practice with anti-dementia drugs:A revised (third) consensus statement from the British Association for Psychopharmacology","volume":"31","author":"O'Brien","year":"2017","journal-title":"J Psychopharmacol"},{"key":"R52-20260525","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00401-017-1705-y","article-title":"Immunological memory to hyperphosphorylated tau in asymptomatic individuals","volume":"133","author":"Pascual","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R53-20260525","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fncel.2018.00172","article-title":"The role of microglia in the spread of Tau:Relevance for tauopathies","volume":"12","author":"Perea","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"R54-20260525","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease:a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"R55-20260525","doi-asserted-by":"crossref","first-page":"2020203","DOI":"10.1080\/19420862.2021.2020203","article-title":"BioPhi:A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning","volume":"14","author":"Prihoda","year":"2022","journal-title":"MAbs"},{"key":"R56-20260525","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"Tau is essential to beta -amyloid-induced neurotoxicity","volume":"99","author":"Rapoport","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R57-20260525","doi-asserted-by":"crossref","first-page":"e057438","DOI":"10.1002\/alz.057438","article-title":"Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial","volume":"17","author":"Reading","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R58-20260525","doi-asserted-by":"crossref","first-page":"e109108","DOI":"10.15252\/embj.2021109108","article-title":"Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency","volume":"41","author":"Reifschneider","year":"2022","journal-title":"EMBO J"},{"key":"R59-20260525","doi-asserted-by":"crossref","first-page":"e2016239118","DOI":"10.1073\/pnas.2016239118","article-title":"Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences","volume":"118","author":"Rives","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R60-20260525","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/1673-5374.343905","article-title":"Synaptopathy in CHMP2B frontotemporal dementia highlights the synaptic vesicle cycle as a therapeutic target","volume":"18","author":"Robbins","year":"2023","journal-title":"Neural Regen Res"},{"key":"R61-20260525","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40478-021-01246-y","article-title":"Synaptic tau:a pathological or physiological phenomenon?","volume":"9","author":"Robbins","year":"2021","journal-title":"Acta Neuropathol Commun 2021"},{"key":"R62-20260525","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1943","article-title":"The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease","volume":"39","author":"Rogaeva","year":"2007","journal-title":"Nat Genet"},{"key":"R63-20260525","doi-asserted-by":"crossref","first-page":"100406","DOI":"10.1016\/j.patter.2021.100406","article-title":"Antibody structure prediction using interpretable deep learning","volume":"3","author":"Ruffolo","year":"2022","journal-title":"Patterns"},{"key":"R64-20260525","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4161\/auto.5.7.9509","article-title":"Targeted therapies and autophagy:new insights from chronic myeloid leukemia","volume":"5","author":"Salomoni","year":"2009","journal-title":"Autophagy"},{"key":"R65-20260525","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J Cell Biol"},{"key":"R66-20260525","doi-asserted-by":"crossref","first-page":"104962","DOI":"10.1016\/j.nbd.2020.104962","article-title":"Shifting paradigms:the central role of microglia in Alzheimer's disease","volume":"143","author":"Schwabe","year":"2020","journal-title":"Neurobiol Dis"},{"key":"R67-20260525","first-page":"5451","article-title":"Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro","volume":"13","author":"Seidler","year":"2022","journal-title":"Nat Commun 2022"},{"key":"R68-20260525","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2014.01.037","article-title":"Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance in chronic sleep restricted rats","volume":"727","author":"She","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"R69-20260525","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0304-3940(95)11902-9","article-title":"Glycogen synthase kinase-3\u03b2phosphorylates tau protein at multiple sites in intact cells","volume":"197","author":"Sperbera","year":"1995","journal-title":"Neurosci Lett"},{"key":"R70-20260525","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol"},{"key":"R71-20260525","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neulet.2017.05.056","article-title":"Microtubule-associated tau contributes to intra-dendritic trafficking of AMPA receptors in multiple ways","volume":"653","author":"Suzuki","year":"2017","journal-title":"Neurosci Lett"},{"key":"R72-20260525","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(22)02480-1","article-title":"The Lancet (2022) Lecanemab for Alzheimer's disease:tempering hype and hope","volume":"400","journal-title":"Lancet"},{"key":"R73-20260525","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS:new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"R74-20260525","doi-asserted-by":"crossref","first-page":"eabm5029","DOI":"10.1126\/sciadv.abm5029","article-title":"Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology","volume":"8","author":"Tsujikawa","year":"2022","journal-title":"Sci Adv"},{"key":"R75-20260525","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease:a randomized clinical trial","volume":"76","author":"Van","year":"2019","journal-title":"JAMA Neurol"},{"key":"R76-20260525","first-page":"9","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van","year":"2022","journal-title":"N Engl J Med"},{"key":"R77-20260525","doi-asserted-by":"crossref","first-page":"n1682","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for Alzheimer's disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"R78-20260525","doi-asserted-by":"crossref","first-page":"31547","DOI":"10.1074\/jbc.M212532200","article-title":"Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"R79-20260525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2017.03.016","article-title":"PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis","volume":"55","author":"Wang","year":"2017","journal-title":"Neurobiol Aging"},{"key":"R80-20260525","doi-asserted-by":"crossref","first-page":"112915","DOI":"10.1016\/j.ejmech.2020.112915","article-title":"Small molecule therapeutics for tauopathy in Alzheimer's disease:walking on the path of most resistance","volume":"209","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"R81-20260525","doi-asserted-by":"crossref","first-page":"e20200785","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J Exp Med"},{"key":"R82-20260525","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R83-20260525","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1073\/pnas.1705867114","article-title":"High-throughput characterization of protein\u2013protein interactions by reprogramming yeast mating","volume":"114","author":"Younger","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R84-20260525","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ajcn\/80.4.862","article-title":"Associations between coffee consumption and inflammatory markers in healthy persons:the ATTICA study","volume":"80","author":"Zampelas","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R85-20260525","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"R86-20260525","doi-asserted-by":"crossref","first-page":"15295","DOI":"10.1038\/ncomms15295","article-title":"Tau association with synaptic vesicles causes presynaptic dysfunction","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"key":"R87-20260525","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1523\/JNEUROSCI.5223-09.2010","article-title":"GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P\/Q-type calcium channel and interrupting SNARE complex formation","volume":"30","author":"Zhu","year":"2010","journal-title":"J Neurosci"},{"key":"R88-20260525","doi-asserted-by":"crossref","first-page":"113818","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem Pharmacol"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.373670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:33Z","timestamp":1787166933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.373670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/1673-5374.373670","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"2023-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}